[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.249.135. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
July 9, 2003

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report—Correction

JAMA. 2003;290(2):197. doi:10.1001/jama.290.2.197

Incorrect Drug Trade Names: In the Special Communication entitled "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report" published in the May 21, 2003, issue of THE JOURNAL (2003;289:2560-2572), there were incorrect drug trade names in Table 4 and Table 5 . On page 2566, in Table 4 , the trade name "Tevetan" should have read "Teveten" and on page 2567, in Table 5 , the trade name "Aldactone" should have read "Aldactazide." In addition, on page 2565, in column 1, the first full sentence should have read "When BP is more than 20 mm Hg above the systolic BP goal or 10 mm Hg above the diastolic BP goal, consideration should be given to initiating therapy with 2 drugs, either as separate prescriptions or in fixed-dose combinations (Figure)."

×